­­

Through CLS commercial collaboration with ClearPoint Neuro in neurosurgery an integrated system is offered for MRI image-guided stereotactic laser ablation with very high precision. By integrating both companies' technologies into one solution, users can identify target tissue, navigate and position the laser applicator with very high accuracy as well as monitor the ablation in near real time.

"The full market release of our joint neurosurgery offering is the fruit of an intense joint collaboration during the last couple of months. Recently, CLS strategy was revised focusing more on neurosurgery within which the companies joint offering recently also was expanded to provide access to approximately 50 percent of the US market for NeuroLITT treatment in the brain. The increased focus on neurosurgery increases our ability to also exploit the full potential of the market as we now enter the full market release in the US," says Dan J. Mogren, CLS CEO.

"This is a truly exciting milestone for ClearPoint, and one that has been years in the making," commented Joe Burnett, President and CEO at ClearPoint Neuro. "We set out to prove that we are one of the most innovative and focused companies in the Neurosurgery space. We were able to walk into the premier stereotactic neurosurgical conference able to demonstrate new laser therapy, new operating room navigation, new brain modeling software, and new access products and new drug delivery preclinical and clinical trial services. This is meaningful innovation that will ultimately benefit our surgical customers and most importantly, many new patients around the world."

The full ClearPoint release, including KOL statements, can be found here (https://ir.clearpointneuro.com/news-events/press-releases/detail/1114/clearpoint-neuro-announces-full-market-release-of).

Contact information:

Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 - (0)705 - 90 11 40

E-mail: dan.mogren@clinicallaser.com

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulant ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB.

For more information about CLS, please visit: www.clinicallaser.se

About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical development services for controlled drug and device delivery. The Company's flagship product, the ClearPoint Neuro Navigation System, has FDA clearance and is CE-marked. ClearPoint Neuro is engaged with healthcare and research centers in North America, Europe, Asia, and South America. The Company is also partnered with the most innovative pharmaceutical/biotech companies, academic centers, and contract research organizations, providing solutions for direct CNS delivery of therapeutics in pre-clinical studies and clinical trials worldwide. To date, thousands of procedures have been performed and supported by the Company's field-based clinical specialist team, which offers support and services to our customers and partners worldwide. For more information, please visit www.clearpointneuro.com.

For more information, please visit: www.clearpointneuro.com.